MHC II deficiency delays B-cell development progression. (A) Expression of differentially expressed genes (at least twofold, P ≤ .05) between MHC II⁻ and MHC II⁺ Fr D WT B-cell precursor samples (left) and of selected MHC II, immunoglobulin, and B-cell differentiation genes in MHC II⁻ or MHC II⁺ WT and Itgax^creH2-Ab1^c Fr D cells (right). (B) Expression level of selected B-cell differentiation genes in the indicated stages of B-cell development. (C) Expression of differentially expressed genes (at least twofold, P ≤ .05, q = 0.05) between WT and Itgax^creH2-Ab1^c Fr D B-cell precursor samples (top) and of the top 7 genes overrepresented in Itgax^creH2-Ab1^c Fr D cells (bottom). WT and Itgax^creH2-Ab1^c FO B cells are also included for comparison. (D) Expression level of selected B-cell stem cell genes in the indicated stages of B-cell development. (E) Correlation of the transcriptional signature of Itgax^creH2-Ab1^c Fr D cells with those of CLP and Fr A cells. Data in panels B and C, and the comparative data in panel D were obtained from ImmGen. (F) Functional pathways revealed by enrichment analysis on genes differentially upregulated (at least twofold, P ≤ .05, q = 0.05) in Itgax^creH2-Ab1^c Fr D cells compared with WT Fr D cells.